Log in

1011 China NT Pharma Group Co., Ltd. HKEX · Hong Kong

China NT Pharma Group Co. (1011) news

China NT Pharma Group Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1011, recorded under Hong Kong. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest China NT Pharma Group Co. news

We have not published a story on China NT Pharma Group Co. yet. When there is news, it will appear here.

Questions about China NT Pharma Group Co.

What is the ticker symbol of China NT Pharma Group Co.?

China NT Pharma Group Co., Ltd. trades under the ticker 1011 on HKEX.

Where is China NT Pharma Group Co. listed?

China NT Pharma Group Co., Ltd. is listed on HKEX.

Which country or territory is China NT Pharma Group Co. listed under?

Our directory records China NT Pharma Group Co., Ltd. under Hong Kong.

What does China NT Pharma Group Co. do?

Our directory classifies China NT Pharma Group Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of China NT Pharma Group Co.?

The ISIN recorded for China NT Pharma Group Co., Ltd. is KYG2114L1133.

Does aibio.space cover China NT Pharma Group Co.?

aibio.space lists China NT Pharma Group Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to China NT Pharma Group Co.?

Companies in our directory listed in the same country and business area as China NT Pharma Group Co.: Sirnaomics, SinoMab Bioscience, CPBIO Holding Company, Genscript Biotech, Sanai Health Industry Group Company, China Traditional Chinese Medicine Holdings Co..

Investor discussion: China NT Pharma Group Co.

Members talk about China NT Pharma Group Co. (1011). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at China NT Pharma Group Co., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: COMPLETION OF CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE. Source

  2. Financings

    Share or debt issue: CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE, APPOINTMENT OF AUDITOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  3. Financings

    Share or debt issue: FURTHER DELAY IN DESPATCH OF CIRCULAR. Source

  4. Financings

    Share or debt issue: DELAY IN DESPATCH OF CIRCULAR. Source

  5. Mergers

    Transaction under the Listing Rules: UPDATE ON IMPLEMENTATION OF REMEDIAL ACTIONS AND KEY FINDINGS OF INTERNAL CONTROL REVIEW. Source

  6. Financings

    Share or debt issue: CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE. Source

  7. Mergers

    Transaction under the Listing Rules: PAST NOTIFIABLE TRANSACTIONS AND CONNECTED TRANSACTIONS IN RELATION TO THE PROVISION OF FINANCIAL ASSISTANCE AND LOAN AGREEMENTS AND DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR. Source

  8. Mergers

    Transaction under the Listing Rules: PAST NOTIFIABLE TRANSACTIONS AND CONNECTED TRANSACTIONS IN RELATION TO THE PROVISION OF FINANCIAL ASSISTANCE AND LOAN AGREEMENTS AND DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR. Source

  9. Mergers

    Transaction under the Listing Rules: COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source

  10. Listings

    Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source

  11. Listings

    Trading status: TERMINATION OF THE SUBSCRIPTION AGREEMENTS IN RELATION TO THE ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND RESUMPTION OF TRADING. Source

  12. Listings

    Trading status: TRADING HALT. Source

  13. Listings

    Trading status: EXCHANGE NOTICE - TRADING HALT. Source

  14. Financings

    Share or debt issue: ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE. Source

  15. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  16. Mergers

    Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT - MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source

  17. Listings

    Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source

  18. Listings

    Trading status: INSIDE INFORMATION AND RESUMPTION OF TRADING. Source

  19. Listings

    Trading status: TRADING HALT. Source

  20. Listings

    Trading status: EXCHANGE NOTICE - TRADING HALT. Source

  21. Mergers

    Transaction under the Listing Rules: DELAY IN DESPATCH OF CIRCULAR. Source

  22. Mergers

    Transaction under the Listing Rules: CLARIFICATION ANNOUNCEMENT - MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source

  23. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE. Source

  24. Mergers

    Transaction under the Listing Rules: COMPLETION OF CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE. Source

  25. Mergers

    Transaction under the Listing Rules: (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 17 FEBRUARY 2025; AND (2) GRANT OF WHITEWASH WAIVER. Source

  26. Mergers

    Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT. Source

  27. Mergers

    Transaction under the Listing Rules: DESPATCH OF THE CIRCULAR IN RELATION TO (1) CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  28. Mergers

    Transaction under the Listing Rules: (1) CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  29. Mergers

    Transaction under the Listing Rules: MONTHLY UPDATE ANNOUNCEMENT ON (1) CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALIZATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE; AND (2) APPLICATION FOR WHITEWASH WAIVER. Source

  30. Mergers

    Transaction under the Listing Rules: PROFIT WARNING AND INSIDE INFORMATION ANNOUNCEMENT UPDATE ON FINANCIAL INFORMATION. Source

Press releases

Headlines of China NT Pharma Group Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT SUPPLEMENTAL INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

  2. HKEXnews

    Notification Letter and Request Form to Non-Registered Holder

  3. HKEXnews

    Notification Letter and Reply Form to Registered Shareholder

  4. HKEXnews

    NOTICE OF EXTRAORDINARY GENERAL MEETING

  5. HKEXnews

    APPOINTMENT OF AUDITOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPLICATION FOR COMPULSORY ENFORCEMENT BY A WHOLLY-OWNED SUBSIDIARY IN RESPECT OF THE SHAREHOLDERS' RIGHT TO INFORMATION OF BEIJING KANGCHEN BIOLOGICAL TECHNOLOGY CO., LIMITED

  7. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT ARBITRATION AWARD

  8. HKEXnews

    APPOINTMENT OF AUDITOR

  9. HKEXnews

    COMPLETION OF CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE

  10. HKEXnews

    CHANGE OF (1) COMPANY SECRETARY, (2) AUTHORISED REPRESENTATIVE AND (3) PROCESS AGENT

  11. HKEXnews

    POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 28 AUGUST 2026

  12. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  13. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT ARBITRATION AWARD

  14. HKEXnews

    Documents on Display

  15. HKEXnews

    CONNECTED TRANSACTION IN RELATION TO LOAN CAPITALISATION INVOLVING SUBSCRIPTION OF SHARES UNDER SPECIFIC MANDATE, APPOINTMENT OF AUDITOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING

  16. HKEXnews

    QUARTERLY UPDATES ON THE IMPLEMENTATION OF ACTION PLANS TO RESOLVE THE DISCLAIMER OF OPINION

  17. HKEXnews

    FURTHER DELAY IN DESPATCH OF CIRCULAR

  18. HKEXnews

    DELAY IN DESPATCH OF CIRCULAR

  19. HKEXnews

    UPDATE ON IMPLEMENTATION OF REMEDIAL ACTIONS AND KEY FINDINGS OF INTERNAL CONTROL REVIEW

  20. HKEXnews

    CHANGE OF CHIEF EXECUTIVE OFFICER

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1011 on TradingView.

Listing details

China NT Pharma Group Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1011, recorded under Hong Kong. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
China NT Pharma Group Co., Ltd.
Ticker
1011
Listing
HKEX
Country or territory
Hong Kong
Business scope
Biotechnology
ISIN
KYG2114L1133
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.